ATLN (Atlantic International) Valuation Rank

View and export this data going back to 2021. Start your Free Trial

What is Atlantic International Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Atlantic International Valuation Rank Related Terms

Thank you for viewing the detailed overview of Atlantic International's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Atlantic International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Atlantic International Corp (NAS:ATLN) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Federal Street, Billerica, MA, USA, 01821

Website

http://www.seqll.com

Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.

Executives

Daniel Robert Jones	officer: President, CEO	317 NEW BOSTON STREET, SUITE 210, WOBURN MA 01801
Douglas Patrick Miscoll	director	317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
David Pfeffer	director	464 IVY AVENUE, HAWORTH NJ 07644
Patrice M. Milos	director	317 NEW BOSTON STREET, SUITE 2010, WOBURN MA 01801
Frances P Scally	officer: CHIEF FINANCIAL OFFICER	66 MELANIE LANE, SYOSSET NY 11791
John Whitcomb Kennedy	officer: CFO, Secretary	166 WINN STREET, WOBURN MA 01801